MRESVIA DIN 02552914
Status: Marketed
Holder: MODERNA BIOPHARMA CANADA CORPORATION
Health Canada record
| Active ingredient(s) | *RSV F-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA 50 MCG |
|---|---|
| Dosage form | Dispersion |
| Route | Intramuscular |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07BX05 RESPIRATORY SYNCYTIAL VIRUS VACCINE |
| Original market date | 17-Jul-2026 |
| Current status date | 17-Jul-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Moderna Biopharma Canada Corporation — licence 3-002801, currently licensed, last inspection rating C (2024-06-10).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 34344 | 2024-11-06 | New Drug Submission (NDS) |